Med-X is preparing for a possible NASDAQ listing (ticker: MXRX)
                                                                                                         

Med-X is preparing for a possible NASDAQ listing (ticker: MXRX). But the real opportunity is now – before global validation changes everything.

In independent lab studies, Med-X's all-natural pesticides have outperformed chemical brands in certain use cases, delivering powerful results without the toxic tradeoffs associated with traditional pest control.

Now, Med-X is pursuing a potential milestone that could redefine the industry: becoming the first botanical pesticide ever pre-qualified by the World Health Organization.

The global biopesticide market is projected to grow nearly 3x by 2030, expanding from $5.8 billion to $17.6 billion as governments move away from synthetic chemicals. A WHO pre-qualification would position Nature-Cide as a globally recognized solution for public health, agriculture, and mosquito-borne disease control – opening doors that most pesticide companies can't access.

Nature-Cide's plant-based formulation prioritizes safety while delivering industrial-grade performance, challenging long-held assumptions about what botanical solutions can achieve on a global scale.

NASDAQ Ticker: MXRX Reserved!
The Real Opportunity to Become a Shareholder Is Now!

Artistic camera angel on Wall St with the words Med-X | BECOME A SHAREHOLDER BEFORE OUR PLANNED NASDAQ LISTING | Reserved Nasdaq Ticker: MXRX | Learn More

Med-X has earned national and international recognition for providing effective alternatives to conventional pesticides across residential, commercial, agricultural, and public-health sectors. Proudly manufactured in the USA, Nature-Cide reflects a commitment to scalable, sustainable innovation.

Already sold through eCommerce giants Amazon, Walmart, and Kroger, and expanding into 41 international markets, Med-X is positioning itself for its next major chapter.

Simpler. Safer. More Effective Pesticides.

Become a Med-X shareholder at $4 per share before their NASDAQ plans unfold.


Disclosures

This is a paid advertisement for Med-X's Regulation A+ Offering.
Please read the offering circular at invest.medx-rx.com

 
 

Notice: Please understand that by opting out from future emails from this advertiser, you are transferring or
authorizing the transfer of your email address to the advertiser listed above. Zacks has no control over how
your email address is used by the advertiser or other third parties. Accordingly, Zacks disclaims all
responsibility and liability arising from the subsequent use of your email address that is made possible by
your submission of your email address above. You are receiving this email from Zacks Investment Research
because you chose to receive messages from Zacks’ partners on the Zacks web site(s). Please note that
Zacks does not produce or endorse this product, and assumes no responsibility for the use thereof.

Your privacy is important to us. Click here to see our Privacy Policy: https://www.zacks.com/privacy.php
If you do not wish to receive further email solicitations from Zacks on behalf of its partners, please click here
to unsubscribe.

Zacks Investment Research
101 N Wacker Drive, Suite 1500
Chicago, IL 60606